middle.news

InhaleRx Secures $38.5M to Accelerate Inhaled Drug Trials for Cancer Pain and Panic Disorder

7:03pm on Monday 2nd of June, 2025 AEST Healthcare
Read Story

InhaleRx Secures $38.5M to Accelerate Inhaled Drug Trials for Cancer Pain and Panic Disorder

7:03pm on Monday 2nd of June, 2025 AEST
Key Points
  • Secured $38.5 million funding agreement with Clendon Biotech Capital
  • Completed Phase 1 trial report for IRX-211 targeting breakthrough cancer pain
  • Filed international patent application under PCT for IRX-211
  • Appointed Ingenu CRO for upcoming Phase 1 and Phase 2 clinical trials
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about IRX
OPEN ARTICLE